Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Cancer Immunology, Immunotherapy |
| Vol/bind | 53 |
| Udgave nummer | 6 |
| Sider (fra-til) | 560-6 |
| Antal sider | 6 |
| ISSN | 0340-7004 |
| DOI | |
| Status | Udgivet - 2004 |
Bibliografisk note
Keywords: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; Case-Control Studies; Diagnosis, Differential; Female; Flow Cytometry; Humans; Interferon-gamma; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Skin NeoplasmsAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients. / Ladekarl, Morten; Agger, Ralf; Fleischer, Charlotte C; Hokland, Marianne; Hulgaard, Egil F; Kirkin, Alexei; von der Maase, Hans; Petersen, Mikkel S; Rytter, Carsten; Zeuthen, Jesper; Gundersen, Hans Jørgen G.
I: Cancer Immunology, Immunotherapy, Bind 53, Nr. 6, 2004, s. 560-6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients
AU - Ladekarl, Morten
AU - Agger, Ralf
AU - Fleischer, Charlotte C
AU - Hokland, Marianne
AU - Hulgaard, Egil F
AU - Kirkin, Alexei
AU - von der Maase, Hans
AU - Petersen, Mikkel S
AU - Rytter, Carsten
AU - Zeuthen, Jesper
AU - Gundersen, Hans Jørgen G
N1 - Keywords: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; Case-Control Studies; Diagnosis, Differential; Female; Flow Cytometry; Humans; Interferon-gamma; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Skin Neoplasms
PY - 2004
Y1 - 2004
N2 - PURPOSE: We wanted to study whether an allogeneic melanoma lysate would be a feasible stimulatory antigen source for detection of a peripheral CD4+ T-cell immune response in patients with medically untreated malignant melanoma. The lysate was produced from a melanoma cell line (FM3.29) which expresses high amounts of melanoma antigens. METHODS: Fresh peripheral blood was incubated with and without lysate for 6 h in the presence of anti-CD28/anti-CD49d MoAb (for costimulation). After flow cytometric estimation of the frequency of CD69+/IFN-gamma+ cells in the CD4+ population, the response to lysate was calculated as the difference between the number of activated IFN-gamma-producing CD4+ cells in the lysate-stimulated and the nonstimulated sample. RESULTS: An immune response to lysate was observed in blood samples from 11 of 15 patients (73%) with metastatic melanoma. A weak response was found in 1 of 4 patients radically operated for localized disease, whereas no responders were seen among 7 healthy donors. The fraction of circulating lysate-activated T cells ranged from 0.0037% to 0.080% of the CD4+ population. A negative result of the assay was found occasionally, especially in donors with high background levels of spontaneous IFN-gamma production, indicating an inhibitory effect of the lysate. CONCLUSIONS: This method for detection of a peripheral T-cell immune response in melanoma patients has several advantages for clinical use. The tumor lysate preparations may contain large numbers of stimulating antigens (known, as well as unknown) and are easily prepared and handled. Potentially, the assay might be useful as a diagnostic tool, a marker of residual or recurrent disease, a prognostic factor, or a predictor or monitor of the effect of antineoplastic therapy including immune-modulating therapy.
AB - PURPOSE: We wanted to study whether an allogeneic melanoma lysate would be a feasible stimulatory antigen source for detection of a peripheral CD4+ T-cell immune response in patients with medically untreated malignant melanoma. The lysate was produced from a melanoma cell line (FM3.29) which expresses high amounts of melanoma antigens. METHODS: Fresh peripheral blood was incubated with and without lysate for 6 h in the presence of anti-CD28/anti-CD49d MoAb (for costimulation). After flow cytometric estimation of the frequency of CD69+/IFN-gamma+ cells in the CD4+ population, the response to lysate was calculated as the difference between the number of activated IFN-gamma-producing CD4+ cells in the lysate-stimulated and the nonstimulated sample. RESULTS: An immune response to lysate was observed in blood samples from 11 of 15 patients (73%) with metastatic melanoma. A weak response was found in 1 of 4 patients radically operated for localized disease, whereas no responders were seen among 7 healthy donors. The fraction of circulating lysate-activated T cells ranged from 0.0037% to 0.080% of the CD4+ population. A negative result of the assay was found occasionally, especially in donors with high background levels of spontaneous IFN-gamma production, indicating an inhibitory effect of the lysate. CONCLUSIONS: This method for detection of a peripheral T-cell immune response in melanoma patients has several advantages for clinical use. The tumor lysate preparations may contain large numbers of stimulating antigens (known, as well as unknown) and are easily prepared and handled. Potentially, the assay might be useful as a diagnostic tool, a marker of residual or recurrent disease, a prognostic factor, or a predictor or monitor of the effect of antineoplastic therapy including immune-modulating therapy.
U2 - 10.1007/s00262-004-0502-3
DO - 10.1007/s00262-004-0502-3
M3 - Journal article
C2 - 14985861
VL - 53
SP - 560
EP - 566
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
SN - 0340-7004
IS - 6
ER -